DSM-Firmenich Share Repurchase Program Update
Analysis based on 52 articles · First reported Jun 02, 2026 · Last updated Jul 28, 2026
The ongoing share repurchase program by DSM-Firmenich is likely to positively impact its stock price by reducing the number of outstanding shares, thereby increasing earnings per share. This action signals confidence from DSM-Firmenich's management and can attract investors looking for companies that return value to shareholders.
DSM-Firmenich, a company in nutrition, health, and beauty, announced on February 9, 2026, its intention to repurchase \u20ac500 million worth of ordinary shares to reduce its issued capital and an additional \u20ac40 million to cover share-based compensation plans. The company commenced the repurchase program on March 12, 2026, for a total of \u20ac540 million. The \u20ac40 million buyback for compensation plans was finalized on March 23, 2026. As of June 26, 2026, DSM-Firmenich has repurchased 4,364,962 shares for a total consideration of \u20ac284.9 million at an average price of \u20ac65.27. Specifically, between June 22 and June 26, 2026, 180,000 shares were repurchased for \u20ac14.1 million at an average price of \u20ac78.53. Between June 1 and June 5, 2026, 437,000 shares were repurchased for \u20ac30.0 million at an average price of \u20ac68.71. The \u20ac500 million share repurchase program is expected to be completed by the end of Q3 2026. DSM-Firmenich is listed on Euronext Amsterdam and SIX Swiss Exchange.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard